Quarterly report pursuant to Section 13 or 15(d)

Business (Details)

v3.20.2
Business (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 11, 2020
shares
Mar. 17, 2020
USD ($)
shares
Feb. 06, 2020
USD ($)
shares
Sep. 04, 2019
USD ($)
shares
Jun. 30, 2020
USD ($)
shares
Apr. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
shares
Feb. 29, 2020
USD ($)
shares
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
product
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Subsequent Event [Line Items]                          
Sale of stock (in shares) | shares         15,180,000                
Net proceeds         $ 35,400,000                
Cash and cash equivalents                 $ 33,391,427 $ 5,250,651 $ 33,391,427 $ 5,250,651 $ 3,609,438
Net loss                 13,458,645 $ 4,016,454 47,857,055 17,693,601  
Net cash used in operating activities                     26,163,954 $ 17,453,929  
Accumulated deficit                 $ 162,147,672   $ 162,147,672   $ 114,290,617
Neurological Clinical And Preclinical Stage Compounds                          
Subsequent Event [Line Items]                          
Number of products in development | product                     3    
Over-Allotment Option                          
Subsequent Event [Line Items]                          
Sale of stock (in shares) | shares 1,980,000       1,980,000                
Armistice Purchase Agreement                          
Subsequent Event [Line Items]                          
Sale of stock (in shares) | shares   1,951,219   1,200,000     1,951,219            
Net proceeds   $ 3,900,000   $ 3,700,000     $ 3,900,000            
Registered Direct Offering                          
Subsequent Event [Line Items]                          
Sale of stock (in shares) | shares     1,306,282         1,306,282          
Net proceeds     $ 5,100,000                    
Armistice | Registered Direct Offering                          
Subsequent Event [Line Items]                          
Sale of stock (in shares) | shares     1,256,282                    
Armistice | Registered Direct Offering | Common stock                          
Subsequent Event [Line Items]                          
Net proceeds               $ 5,100,000          
AYTU | Common stock                          
Subsequent Event [Line Items]                          
Net proceeds           $ 12,800,000